Jacob J. Orme, M.D., Ph.D. - Doctors ...

Dr. Jacob Orme

Claim this profile

Mayo Clinic in Rochester

Studies Prostate Cancer
Studies Melanoma
6 reported clinical trials
17 drugs studied

Area of expertise

1Prostate Cancer
Jacob Orme has run 3 trials for Prostate Cancer. Some of their research focus areas include:
Stage IV
SPOP positive
2Melanoma
Jacob Orme has run 1 trial for Melanoma. Some of their research focus areas include:
PD-L1 positive

Affiliated Hospitals

Image of trial facility.
Mayo Clinic In Rochester
Image of trial facility.
Dana-Farber - Harvard Cancer Center LAO

Clinical Trials Jacob Orme is currently running

Image of trial facility.

Atezolizumab + Chemotherapy

for Neuroendocrine Carcinoma

This trial is testing a new treatment combining an immune-boosting drug with standard chemotherapy for patients with a specific type of aggressive cancer that has spread. The goal is to help the immune system fight the cancer and use chemotherapy to kill cancer cells.
Recruiting1 award Phase 2 & 310 criteria
Image of trial facility.

Radiation and Hormone Therapy

for Prostate Cancer

This phase II trial studies the effects of stereotactic body radiation therapy (SBRT) and the timing of treatment with androgen receptor pathway inhibitor (ARPI) plus androgen deprivation therapy (ADT) in treating patients with hormone sensitive prostate cancer that has spread from where it first started to other places in the body (metastatic), and that has come back after a period of improvement (recurrent). SBRT is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body (except the brain). The total dose of radiation is divided into smaller doses given over several days. This type of radiation therapy helps spare normal tissue. Androgen can cause the growth of prostate cells. ADT lowers the amount of androgen made by the body. This may help stop the growth of tumor cells that need androgen to grow. Androgen receptor pathway inhibitors work by blocking the effects of androgen to stop the growth and spread of tumor cells. Giving SBRT alone with watchful waiting may be as effective in treating prostate cancer as giving SBRT together with ARPI and ADT.
Recruiting1 award Phase 24 criteria

More about Jacob Orme

Clinical Trial Related3 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Jacob Orme has experience with
  • Enzalutamide
  • Hyaluronidase-zzxf
  • Pertuzumab
  • Trastuzumab
  • M1774
  • Abiraterone

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Jacob Orme specialize in?
Is Jacob Orme currently recruiting for clinical trials?
Are there any treatments that Jacob Orme has studied deeply?
What is the best way to schedule an appointment with Jacob Orme?
What is the office address of Jacob Orme?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security